PART B - FEE(S) TRANSMITTAL

send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE C mmissioner for Patents P.O. B x 1450 Alexandria, Virginia 22313-1450

or Fax (703) 746-4000

or transmitting the ISSUI og the Patent, advance ord erwise in Block 1, by (a)	E FEE and PUBLIC lers and notification specifying a new co	CATION FEE (if requ of maintenance fees orrespondence address	nired). Blocks I through 4 sl will be mailed to the current c; and/or (b) indicating a sepa	hould be completed where correspondence address as arate "FEE ADDRESS" for	
CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1) 23115 7590 10/21/2003 TAKEDA PHARMACEUTICALS NORTH AMERICA, INC INTELLECTUAL PROPERTY DEPARTMENT 475 HALF DAY ROAD SUITE 500			Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below.		
(Date)					
			T T		
F			<u> </u>	CONFIRMATION NO.	
10/019,094 04/12/2002 Jun-Ichi Kawakami 2617 USOP 4051 TITLE OF INVENTION: PROCESS FOR THE PREPARATION OF IMIDAZOLE DERIVATIVES					
ISSUE FE	E PL	JBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE	
\$1330		\$0	\$1330	01/21/2004	
ART UNI	T CI	ASS-SUBCLASS	٦		
1626	<u>, </u>	548-335100			
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. The Address form PTO/SB/122 attached. The Address indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.					
3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) Takeda Chemical Industries, Ltd. Osaka, Japan					
Please check the appropriate assignee category or categories (will not be printed on the patent); undividual XX corporation or other private group entity up government					
4a. The following fee(s) are enclosed: 4b. Payment of Fee(s):					
``					
2					
e Fee and Publication Fee ((if any) or to re-apply	~			
esh (Date)					
Reg. No. 43,032 NOTE; The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.		01 FC:15	01 1330.00 DA	500799 10019094	
J.S.C. 122 and 37 CFR 1.1 diding gathering, preparing, me will vary depending to you require to complete e sent to the Chief Informment of Commerce, Al MPLETED FORMS TO ria, Virginia 22313-1450. 5, no persons are require	4. Ins collection is and submitting the upon the individual e this form and/or lation Officer, U.S. exandria, Virginia THIS ADDRESS.	02 10:80	OI 9.00 DH		
	ISSUE FE S1330 ART UNI 1626 TO BE PRINTED ON TI fied below, no assignee da being submitted under sep ies, Ltd. categories (will not be printed by the categories) required) will not be according to the categories (will not be printed by the categories) required) will not be according to the categories (will not be printed by the categories) required) will not be according to the categories (will not be printed by the categories) required) will not be according to the categories (will not be printed by the categories) required) will not be according to the categories (will not be printed by the categories) required) will not be according to the categories (will not be printed by the categories) required) will not be according to the categories (will not be printed by the categories) required) will not be according to the categories (will not be printed by the categories) required) will not be according to the categories (will not be printed by the categories) required) will not be according to the categories (will not be printed by the categories) required) will not be according to the categories (will not be printed by the categories) required of the categories (will not be printed by the categories) required of the categories (will not be printed by the categories) required of the categories (will not be printed by the categories) required of the categories (will not be printed by the categories) required of the categories (will not be printed by the categories) required of the categories (will not be printed by the categories) required of the categories (will not be printed by the categories) required of the categories (will not be printed by the categories) required of the categories (will not be printed by the categories) required of the categories (will not be printed by the categories) required of the categories (will not be printed by the categories) required of the categories (will not be printed by the categories) required of the categories (will not be printed by the categori	FIRST NAMED INVEN Jun-Ichi Kawakar PREPARATION OF IMIDAZOLE DERIVATI ISSUE FEE PI \$1330 ART UNIT IGE Ge of Correspondence Indication form ed. Use of a Customer A TO BE PRINTED ON THE PATENT (print of fied below, no assignee data will appear on the being submitted under separate cover. Complet (B) RESIDENCE: (CIT ies, Ltd. Osaka categories (will not be printed on the patent); 4b. Payment of Fee(s): A check in the am Payment by credit Es A Check in the am Payment by credit Indication fee (if any) or to re-apply A check in the am Payment by credit The Director is hoposit Account Nu Prese and Publication Fee (if any) or to re-apply Completed to the printed on the patent; Completed to the printed on the patent; A Completed to the printed on the patent; A Completed to the printed on the patent; A check in the am Payment by credit The Director is hoposit Account Nu Payment by credit A Completed to the printed on the patent; Completed to the printed on the patent; A check in the am Payment by credit A check in the am Payment of Fee(s): A check in the am Payment by credit A court on the payment of Fee(s): A check in the am A coppleted to the pay	TREATMENT SINCE PUBLICATION FEE	FEES T NAMED INVENTOR ATTORNEY DOCKET NO. Jun-1chi Kawakami 2617 USOP PREPARATION OF IMIDAZOLE DERIVATIVES ISSUE FEE PUBLICATION FEE TOTAL FEE(S) DUE \$1330 \$0 \$1330 ART UNIT CLASS-SUBCLASS 1626 \$48-335100 ART UNIT CLASS-SUBCLASS 1627 \$130 \$1 \$2\$ registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered patent attorneys or agents OR, alternatively, (2) the name of a single firm (having as a member as registered patent attorneys or agents or agents of the order of a single firm (having as a member as registered patent attorneys or agents or agents of the order of a single firm (having as a member as registered patent attorneys or agents or agents of the order of a single firm (having as a member as registered patent attorneys or agents. If no name is listed, no name attorneys or agents of the order of a single firm (having as a member as registered patent attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agents. If no name is listed, no name attorneys or agen	

TRANSMIT THIS FORM WITH FEE(S)

OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTOL-85 (Rev. 10/03) Approved for use through 04/30/2004.

Express mail # EN 410709753 US

DIPE IN 1.6 2004

١

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:

10/019,094

Filed:

04/12/2002

1st Inventor:

J. Kawakami

For:

Process for the Preparation of Imidazole

Derivatives

Atty. Dkt. No.

2617 US0P

Art Unit:

1626

Examiner:

R. Shiao

Allowed:

10/21/2003

Batch:

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 410709753 US

DATE IN:

January 16, 2004

Itemized Papers/Items:

- 1. This certificate and a Return Receipt Postcard (2 pages)
- 2. Issue Fee Transmittal (1 page X 2)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on this date, 1/16/04

Dated: 1/16/04

Gail L. Winokur

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department Suite 500, 475 Half Day Road Lincolnshire, IL 60069 USA